Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?

BACKGROUND: Hemophilia A (HA) is an X-linked recessive bleeding disorder characterized by qualitative and quantitative deficiency of factor VIII (FVIII). The development of inhibitor antibodies against FVIII is the most challenging complication of treatment. Mutations in the FVIII gene is one of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherief, Laila M., Gaber, Osama A., Youssef, Hala Mosaad, Sherbiny, Hanan S., Mokhtar, Wesam a, Ali, Asmaa A. A., Kamal, Naglaa M., Abdel Maksoud, Yehia H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488666/
https://www.ncbi.nlm.nih.gov/pubmed/32928254
http://dx.doi.org/10.1186/s13052-020-00878-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488666/
https://www.ncbi.nlm.nih.gov/pubmed/32928254
http://dx.doi.org/10.1186/s13052-020-00878-5

Ejemplares similares